Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

NCT03361865 PHASE3 COMPLETED Results posted

The purpose of this study was to evaluate the efficacy and safety of pembrolizumab + epacadostat vs pembrolizumab + placebo in participants with cisplatin-ineligible urothelial carcinoma.

Details

Lead sponsor	Incyte Corporation
Phase	PHASE3
Status	COMPLETED
Enrolment	93
Start date	Mon Dec 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Aug 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• UC (Urothelial Cancer)

Interventions

• Pembrolizumab
• Epacadostat
• Placebo

Countries

France, Italy, Japan, Netherlands, Russia, Ukraine, Belgium, Taiwan, Ireland, United Kingdom, Germany, Israel, Poland, South Korea, Canada, Australia, United States, Spain